Author: cpereira@noblefcm.com

MustGrow Biologics Corp. (MGROF) – Corporate Presentation

Posted on by cpereira@noblefcm.com


Friday, April 28, 2023

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Webinar. We had the opportunity to participate in MustGrow’s webinar presentation on recent corporate progress, biological industry developments, and upcoming catalysts. The key takeaways, in our view: MustGrow and its partners continue to make progress toward commercialization of the Company’s unique technology; revenues could begin within 12 months; the TAM is large and growing; and stricter governmental regulations across the world highlight the need for sustainable products like MustGrow’s products.

TAM. The global pesticide market grows at a 3.5% CAGR and should hit $82 billion by 2030, with the fertilizer market growing at a 2.5% CAGR to $242 billion by 2030. But with an ever increasing movement to limit or outright ban certain pesticide and fertilizer products, the TAM for MustGrow grows even faster.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Permex Petroleum (OILCF) – Company Presentation Provides A Few Company Updates

Posted on by cpereira@noblefcm.com


Thursday, April 27, 2023

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

CEO/P Mehran Ehsan made a presentation at the Planet Microcap Showcase on April 26. The short, ten-minute presentation largely restated the company’s case that there is a disconnect between its asset value and its stock price. Mr. Ehsan once again pointed to a reserve study of its properties that values its properties at $428 million using a 10% discount rate versus the stock’s current enterprise value of $9 million. If one were to value the company based on just proved reserves, the value would still be $128 million. In fact, the value from only wells currently producing is $12 million, still above the current market capitalization.

Management believes the disconnect stems from its listing on the OTCQB exchange which limits manager investments in the company. The company has dropped plans to list on the New York Stock Exchange and now plans to list on the NASDAQ exchange. We believe such a move is prudent and that it will help reduce the valuation disconnect. This is especially important given Permex’s need for capital to drill out additional wells. Along those lines, management indicated that it plans to convert a vertical well drill last fall to a horizontal well. The drilling will use $1.1 million of the $1.67 million in cash on hand and take a few months to complete.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Vera Bradley (VRA) – Additional Corporate Reorganization and Cost Reduction Plans

Posted on by cpereira@noblefcm.com


Thursday, April 27, 2023

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Placing Her Stamp. Vera Bradley CEO Jackie Ardrey announced additional corporate organizational changes as well as targeting $12 million of incremental cost reductions, the majority of which should fall to the bottom line. We view the announcement as Ms. Ardrey putting her stamp on the Company from a management perspective, while right-sizing the expense structure of the Company.

New CFO. Michael Schwindle will join Vera Bradley as CFO on May 8th. Mr. Schwindle has previously worked with CEO Ardrey. Mr. Schwindle is a 30-year retail industry veteran, including 15 years as a CFO in such firms as accessory and jewelry retailer Claire’s, Fleet Farm, Payless ShoeSource, Harry & David, and Musician’s Friend. Mr. Schwindle began his career at Deloitte & Touche LLP.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Beasley Broadcast Group (BBGI) – Delivers A Solid Quarter

Posted on by cpereira@noblefcm.com


Thursday, April 27, 2023

Beasley Broadcast Group, Inc. owns and operates 61 stations (47 FM and 14 AM) in 15 large- and mid-size markets in the United States. Approximately 20 million consumers listen to the Company’s radio stations weekly over-the-air, online and on smartphones and tablets, and millions regularly engage with the Company’s brands and personalities through digital platforms such as Facebook, Twitter, text messaging, digital and web applications and email. The Overwatch League’s Houston Outlaws esports team is a wholly owned subsidiary. The Company also owns BeasleyXP, a national esports content hub, and AXLR-R8, a Rocket League Championship Series team, in its esports portfolio. For more information, please visit www.bbgi.com.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q1 results. The company reported revenue of $57.8 million and adj. EBITDA of $2.8 million, beating our upwardly revised estimates by 1.8% and 6.3%, respectively. The better than expected results were driven by strong digital revenue of $10 million, an increase of 27% from the prior year period, and $4.3 million in sports betting advertising. 

Robust digital growth. From Q1 2019 to Q1 2023, the company grew digital revenue at a CAGR of 30% and now Digital represents 17% of total company revenue. Given the anticipated strong digital revenue growth, management appears to be on target for Digital to be 20% to 30% of total revenue for full year 2023, and 40% in 2024. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The GEO Group (GEO) – Solid First Quarter Results

Posted on by cpereira@noblefcm.com


Wednesday, April 26, 2023

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q23 Results. Revenue for the quarter came in at $608.2 million, up from $551.2 million a year ago. Adjusted EBITDA totaled $130.9 million, EPS was $0.19, and adjusted EPS $0.22. In the year ago period, GEO reported $125.2 million, $0.26, and $0.31, respectively. We had forecast $607 million, $128 million, $0.21, and $0.21, respectively.

ISAP the Sequential Delta. Electronic monitoring revenue declined to $132.6 million in 1Q23 down from $149.8 million in 4Q22, with the remaining businesses up $4.3 million sequentially. Notably, populations under the program have been relatively stable since the beginning of March. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Schwazze (SHWZ) – Growing to Everest Heights

Posted on by cpereira@noblefcm.com


Wednesday, April 26, 2023

Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Acquisition. Schwazze announced the Company signed definitive documents to acquire certain assets of Sucellus, LLC. In the proposed acquisition, the Company will manage Everest Apothecary, Inc. and will be for $38 million in a combination of cash, a four-year seller note, and Company stock. It is expected to close in 2Q23.

Who is Everest? Everest is a not-for-profit company established in 2016 consisting of 14 dispensaries located in Albuquerque, Santa Fe, Las Cruces, Los Lunas, Sunland Park, Belen, and Texico, and also consists of approximately 16,000 square feet of cultivation and a 8,500 square foot manufacturing facility. The acquisition is similar to the R. Greenleaf acquisition done by Schwazze in 2022, where 10 dispensaries, four cultivation facilities, and a manufacturing facility were acquired for $42 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Defense Metals Corp. (DFMTF) – Pilot Plant Program Moves to Phase II

Posted on by cpereira@noblefcm.com


Wednesday, April 26, 2023

Defense Metals Corp. is a mineral exploration and development company focused on the acquisition, exploration and development of mineral deposits containing metals and elements commonly used in the electric power market, defense industry, national security sector and in the production of green energy technologies, such as, rare earths magnets used in wind turbines and in permanent magnet motors for electric vehicles. Defense Metals owns 100% of the Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Pilot plant program. The Wicheeda REE project pilot plant is being configured to produce a high purity rare earth precipitate suitable as feed stock for a rare earths element (REE) separation plant. The objective of the pilot plant is to demonstrate, at a larger scale, the processing of Wicheeda flotation concentrate to produce rare earths using the acid bake hydrometallurgy process and to collect data for a preliminary feasibility study which is expected to be completed in the first quarter of 2024.

On to Phase II. Phase I of the hydrometallurgical pilot plant operation was completed successfully (please refer to our research note dated April 13) and provided an opportunity to explore areas of the process where the efficiency of the hydrometallurgical process could be improved. Changes have been incorporated in the Phase II pilot plant program which began on April 24 and will run for 10 days. The data from the pilot plant will be used in the preliminary feasibility study.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – Loss of a Managed Contract

Posted on by cpereira@noblefcm.com


Wednesday, April 26, 2023

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Contract Loss. Yesterday, CoreCivic announced the State of Oklahoma will not renew the lease agreement for the company-owned, 2,400-bed North Fork Correctional Facility (NFCF) upon the lease expiration on June 30, 2023. According to the release, the State was facing staffing challenges at the NFCF that limited the facility’s utilization and were exacerbated by the difficult employment market since the beginning of the COVID-19 pandemic. The lease generated $12.2 million of revenue in 2022.

Competitive Pressure. CoreCivic also noted that since commencing the lease of the NFCF in 2016, other privately owned correctional capacity became available to the state of Oklahoma and impacted the competitive landscape for renewal of the Company’s lease agreement. We would note The GEO Group just announced a new lease contract with Oklahoma for its previously idle Great Plains facility. Great Plains is about 50 miles from Oklahoma City compared to about 130 miles for NFCF, which may make staffing less of an issue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Century Lithium Corp. (CYDVF) – Moving Right Along

Posted on by cpereira@noblefcm.com


Wednesday, April 26, 2023

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Feasibility study expected by mid-year. The Clayton Valley feasibility study is advancing and expected to be released mid-2023. The main categories of work outstanding are: 1) project execution plan and schedule, 2) draft estimates, 3) draft report, 4) final capital and operating cost estimates, 5) final engineering report, and 6) final technical report. The feasibility study is being led by Wood PLC, supported by Global Resource Engineering for the mining component, thyssenKrupp Nucera AG & Co. for the design of the chlor-alkali plant, and Saltworks for the extraction process.

Collaboration with Koch. Apart from the feasibility study, Century Lithium is collaborating with Koch Technology Solutions (KTS) in the application of its proprietary Li-Pro direct lithium extraction (DLE) process. Koch Engineered Solutions, the owners of the Lionex direct lithium extraction technology, will provide the engineering design and costs for the full-scale DLE portion of the processing plant for the Clayton Valley Project.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Baudax Bio (BXRX) – Full Top Line BX1000 Phase II Results Presented

Posted on by cpereira@noblefcm.com


Wednesday, April 26, 2023

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Gregory Aurand, Senior Vice President, Equity Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Key Opinion Leader Webinar.  In conjunction with the full top line data release, yesterday Baudax Bio held a key opinion leader webinar to discuss the results in greater detail.  Led by Gerri Henwood, President and CEO, and Stuart McCallum, Chief Medical Officer, the webinar featured Dr. Todd Bertoch, CEO of JBR Clinical Research, and Dr. Harold Minkowitz, Associate Director at MD Anderson Cancer Center Dept. of Anesthesiology and Perioperative Medicine.

BX1000 patient data was “spectacular”.  Similar to the prior two interim analyses, the full 79-patient (of the four 20-patient cohorts one patient in the rocuronium arm was not evaluated due to issues with the endotracheal tube) trial showed that all BX1000 patients met Good or Excellent intubating conditions at 60 seconds. From a safety perspective, treatment emergent side effects like nausea were comparable to rocuronium (current standard) in all BX1000 cohorts. There will be 28-day patient safety follow-up and this data could be available in around four weeks.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

PDS Biotechnology Corp. (PDSB) – Roundtable on IL-12 Highlights PDS0301

Posted on by cpereira@noblefcm.com


Monday, April 24, 2023

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

KOL Discussion Of IL-12. PDL Biotechnology held a Roundtable Discussion on cancer therapy with IL-12 and its proprietary, tumor-seeking version, PDS0301. The panel was moderated by Dr. Lauren Wood, Chief Medical Officer, and featured two distinguished scientists from the National Cancer Institute. The presentations highlighted the distinctions between PDL0301 and recombinant IL-12, with clinical data from trials testing both drugs.

Comparisons Between IL-12 and PDS0301. The presentations pointed out the differences between IL-12 and PDS0301, the proprietary version developed by the NCI and licensed by PDS. One of the key points is that PDS0301 is an antibody linked to IL-12. The antibody domain targets and binds to cancer cell DNA that has been released from dead or dying cancer cells. This concentrates PDS0301 in the tumor, then the IL-12 portion stimulates an immune response. This differs from other trials that have used recombinant IL-12 to stimulate an immune response. In comparison, systemic rIL-12 delivery or targeting technologies have resulted in lack of efficacy, systemic side effects, or both.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Onconova Therapeutics (ONTX) – Data Presented on Narazaciclib Targets and Mechanisms

Posted on by cpereira@noblefcm.com


Thursday, April 20, 2023

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data Presented At AACR Annual Meeting. Onconova presented two posters at the American Association of Cancer Research annual meeting, held April 14 to April 19. These posters from preclinical studies gave additional details on the activity, targets, and mechanism of action for narazaciclib, its CDK4/6 inhibitor, and comparisons with other approved CDK4/6 inhibitors.

Study On Naraciclib Targets. The first poster showed that narazaciclib inhibits CDK4/6 as well as additional kinases in cancer progression and metastasis. Data included the BUB1 kinase that is overexpressed in breast and uterine cancers, showing correlations between BUB1 expression and poor survival. BUB1 was inhibited by narazaciclib, but not palbociclib (Ibrance, from Pfizer) or abemaciclib (Verzenio, from Lilly). The poster also presented data showing that narazaciclib may lead to the expression of immune modulators in tumor cells that lead to anti-tumor immunity, an important mechanism for preventing recurrence.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Direct Digital Holdings (DRCT) – Raising Estimates

Posted on by cpereira@noblefcm.com


Thursday, April 20, 2023

Michael Kupinski, Director of Research – Digital, Media & Technology Analyst, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Revenue restatement. Certain invoices were not sent in a timely manner and roughly $1.4 million in revenue was not captured in its preliminary 2022 full year results. As such, full year revenue was $89.4 million rather than $88.0 million, as previously reported, and adj. EBITDA was $10.1 million rather than $8.8 million.

Favorable operating momentum. The restatement positively impacted 2022 results and, importantly, management re-iterated full year 2023 guidance of revenue between $118 million to $122 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.